Israeli biotech XTL Biopharmaceuticals is gearing up for a Phase II trial of its hCDR1 compound for the treatment of Lupus (Systemic Lupus Erythematosus – SLE). HCDR1 is the first new treatment for Lupus in 50 years and was given special orphan status by the United States FDA.
http://www.xtlbio.com/wp-content/uploads/2013/06/XTLBIO-2014.03.25-New_Consultant_Release.pdf